The 200,000ft2 facility in Kakegawa is expected to be operational by the second quarter of 2016
Catalent Pharma Solutions, a global provider of drug delivery technologies is to introduce clinical supply services at its 200,000ft2 cGMP facility in Kakegawa, Japan.
The site, which has been providing oral drug development and manufacturing solutions for more than 40 years, will offer clinical supply solutions to meet the needs of both domestic and global clinical trial sponsors.
Catalent says building work has already started at the facility and should be validated and operational in the second quarter of this year.
The plant will provide project and clinical supply management, comparator sourcing, secondary packaging and labelling, clinical storage, distribution, and drug return and destruction.
The services offered will complement those from Catalent’s existing operations in Asia-Pacific, which comprise a full service primary and secondary clinical packaging and storage facility in Shanghai, a secondary packaging and clinical storage facility in Singapore, and a regional depot network.
Wetteny Joseph, Catalent’s President of Clinical Supply Services, said the Kakegawa site will play a significant role in serving the market in Japan, the second-largest pharmaceutical market worldwide and a key country for new global and domestic clinical trials.
'The Asia-Pacific region is a key part of our strategic growth initiatives and our site in Japan adds to Catalent’s overall clinical supply capabilities in the region, where we will continue to make investments necessary to help meet customers’ existing and future clinical trial demands.'
With facilities in the US, UK, Germany, Singapore, and China, and a network of more than 50 audited depots, Catalent’s clinical supply services team is able to handle a broad range of international compliance and distribution requirements, that can help to speed up clinical trials and ensure that customers are reliably supplied where and when needed around the globe.